Litmus Health, the research-ready infrastructure platform for real-world data has announced the release of the next generation of their platform focused on reliable data engineering, data quality, and flexible deployment. The end-to-end platform supports the entire trial process: from data collection at the point of experience to laboratory analytics that can inform decision making.
Pharma Industry Increasingly Turning to Real-World Data
The pharmaceutical industry has been increasingly looking to real-world data to validate patient reporting, as well as to develop novel endpoints for discovery during research and development and all phases of clinical trials. However, the industry has faced challenges in data integration due to the absence of industry-wide data standards and complexity surrounding data integrity. Of the pharma companies either establishing or currently investing in real-world data tools and platforms, only 45% currently have capabilities mature enough to do so. The same survey found that 65% of pharma respondents cited a lack of access to the external data necessary to make real-world analyses valuable.
Efforts to learn from data and make predictions based on them often fail due to poor data quality, lack of standardization and interoperability, and non-actionable insights derived from those data. This is especially true with clinical data collected from wearables, sensors, and other devices, due to the complexities of synchronizing multiple devices, sensors, and data streams. By providing a research-ready platform for high velocity, high volume standardized data collection and storage, Litmus frees researchers and clinicians from the costly and time-consuming data engineering projects that have stymied their efforts to integrate novel endpoints.
Research-Ready Infrastructure for Real Life Data
The Litmus platform collects data directly from hundreds of data sources, positioning it for later analytics work with zero wrangling. Integrate multiple sets and streams with ease. The platform leverages distributed storage technologies and containerization to allow for flexible partitioning of data based on team security needs. The platform has been built to meet enterprise infrastructure best practices, creating a fault-tolerant and scalable backbone for clinical data.
Integration with Wearables
In addition to upgrades to allow for greater auditability and on-prem capabilities, the upgraded platform now supports Actigraph in addition to FitBit and Garmin. As the leading provider of wearable physical activity and sleep monitoring solutions for the global scientific community, Actigraph enables leading pharmaceutica to improve study efficiency, data quality, and patient outcomes. By supporting Actigraph integrations, the Litmus platform fulfills industry demand for medical-grade sensors built into clinical trial protocols.
Takeda + UChicago Study/Results
As the industry moves to integrate wearables into trials, the early results are promising. Litmus Health is in the midst of a 500 patient, 3-year study funded by Takeda Pharmaceuticals and run by Dr. David Rubin’s Digestive Diseases Center at the University of Chicago. The partnership has already yielded promising initial results, including the discovery that passive biosensor monitoring can be used to predict elevated biomarkers indicative of inflammation in IBD, effectively tracking flares as they relate to everyday activities like patient activity and heart rate.
Why It Matters
We’re now at a point where everyone is hungry to put real-world data to use, and they’re all looking for a solution that supports the entire trial process,” said Daphne Kis, CEO of Litmus Health. “Since the beginning, we’ve built Litmus Health to steward these data responsibly from the point of collection to actionable insights. Our mission has always been to turn the whole world into a clinical trial, and we’re so excited to debut the next generation of our platform that will scale that mission to researchers and clinicians everywhere.”
